In short
A new clinical trial is exploring the potential of Magrolimab (also known as Hu5F9‐G4) in combination with intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). This Phase 2 study, called MAGROLIC, aims to evaluate the effectiveness and safety of this treatment approach for patients who are eligible for stem cell transplantation.
At a glance
- Study Name
- MAGROLIC
- Drug
- Magrolimab (Hu5F9‐G4)
- Trial Phase
- Phase 2
- Conditions Studied
- Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
- Treatment Approach
- Magrolimab plus intensive chemotherapy
- Primary Endpoint
- Best complete remission rate during induction chemotherapy
- Key Secondary Endpoints
- Overall Survival, Event-Free Survival, Relapse-Free Survival
- Eligible Patients
- Newly diagnosed AML or MDS-IB-2, intermediate or poor-risk, eligible for intensive chemotherapy and stem cell transplantation
- Maximum Daily Dose
- 30 mg/kg
- Administration Route
- Intravenous infusion
What is Magrolimab?
Magrolimab, also known as HU5F9‐G4, is a new medication being studied for the treatment of certain blood cancers. It is a type of drug called an immunoglobulin, which is a protein that helps your immune system fight diseases. Magrolimab is given as a solution for infusion, which means it is delivered directly into your bloodstream through a vein.
Medical Conditions Treated
Magrolimab is being investigated for the treatment of two main conditions:
- Acute Myeloid Leukemia (AML): This is a type of cancer that affects the blood and bone marrow. It causes rapid growth of abnormal white blood cells.
- High-risk Myelodysplastic Neoplasia: This is a group of disorders where the bone marrow doesn't produce enough healthy blood cells. It's considered "high-risk" when it's more likely to progress to AML.
How Magrolimab is Used
In the clinical trial, Magrolimab is being used in combination with intensive chemotherapy for patients who are newly diagnosed with AML or high-risk myelodysplastic syndrome. The treatment is intended for patients who are planning to undergo allogeneic stem cell transplantation, which is a procedure where healthy stem cells from a donor are used to replace the patient's diseased bone marrow.
Magrolimab is given intravenously (through a vein) at a maximum dose of 30 mg/kg (milligrams per kilogram of body weight). The treatment period can last up to 4 weeks.
Clinical Trial Details
The clinical trial for Magrolimab is called MAGROLIC. It's a Phase 2, single-arm, open-label study. Here's what these terms mean:
- Phase 2: This stage of clinical research focuses on determining how well the drug works and continues to assess its safety.
- Single-arm: All participants in the study receive the same treatment; there's no comparison group.
- Open-label: Both the researchers and the participants know which treatment is being given.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key inclusion criteria are:
- Having AML or high-risk myelodysplastic syndrome according to specific medical criteria.
- Being classified as "intermediate or adverse risk" according to certain guidelines.
- Planning to undergo intensive chemotherapy followed by allogeneic stem cell transplantation.
Some reasons why a patient might not be eligible include:
- Not being suitable for intensive chemotherapy.
- Having received prior treatment for AML or high-risk myelodysplastic syndrome (except for a medication called hydroxyurea).
- Having a specific genetic mutation called FLT3.
- Having inadequate function of the heart, lungs, kidneys, or liver.
Study Objectives and Endpoints
The main goal of this study is to see how well Magrolimab works when combined with intensive chemotherapy. Researchers will look at several factors, including:
- Complete remission rate: This is the main measure of success, looking at how many patients achieve complete remission after treatment.
- Overall survival: How long patients live after starting the treatment.
- Event-free survival: The time from the start of treatment until the disease worsens or the patient dies.
- Relapse-free survival: For patients who achieve remission, how long they stay in remission.
- Rate of stem cell transplantation: How many patients are able to proceed to stem cell transplantation.
- Quality of life: How the treatment affects patients' overall well-being.
Potential Benefits and Risks
While Magrolimab shows promise in treating AML and high-risk myelodysplastic syndrome, it's important to remember that it's still being studied. The potential benefits include improved treatment outcomes and the possibility of proceeding to stem cell transplantation. However, as with any medical treatment, there may be risks and side effects.
The study will carefully monitor all adverse events (side effects) during the treatment. These will be graded according to their severity and recorded to ensure patient safety.
It's crucial for patients to discuss the potential benefits and risks of participating in this clinical trial with their healthcare providers. They can provide more detailed information based on individual health conditions and circumstances.